Zhichao Zhou, Fengcheng Lin, Wenqi Wei, Dongmei Liu
{"title":"四个基因七种靶向药物或可治疗糖尿病肾病和急性冠状动脉综合征","authors":"Zhichao Zhou, Fengcheng Lin, Wenqi Wei, Dongmei Liu","doi":"10.1620/tjem.2024.J048","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes nephropathy (DN) is a main risk factor for acute coronary syndrome (ACS), but the molecular mechanism is unknown. This research used bioinformatics approaches to uncover potential molecular mechanisms and drugs for DN and ACS. GSE142153 and GSE19339 were downloaded from the Gene Expression Omnibus (GEO) database. The mutually different expression genes (DEGs) detected in the GSE142153 and GSE19339 datasets were then subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. After a protein-protein interaction network (PPI) analysis, hub genes and transcriptional regulators were tracked by Cytoscape Soft. Finally, potential therapeutic drugs were predicted by the DGIDB drug database. This study identified 274 mutual DEGs from the DN and ACS datasets. Functional analyses indicated that \"RNA polymerase II\" and the \"IL-17 signaling pathway\" might play an important role in DN and ACS. Through PPI network construction, the top ten genes were identified. Hub gene and transcription factor interactions were constructed. Seven drugs targeted at VEGFA, IL6, IL1B, and IL1A were evaluated. Four genes and seven drugs were evaluated that could provide a novel perspective for DN and ACS in the future.</p>","PeriodicalId":23187,"journal":{"name":"Tohoku Journal of Experimental Medicine","volume":" ","pages":"1-8"},"PeriodicalIF":1.7000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Four Genes with Seven Targeted Drugs might be Treatment for Diabetic Nephropathy and Acute Coronary Syndrome.\",\"authors\":\"Zhichao Zhou, Fengcheng Lin, Wenqi Wei, Dongmei Liu\",\"doi\":\"10.1620/tjem.2024.J048\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Diabetes nephropathy (DN) is a main risk factor for acute coronary syndrome (ACS), but the molecular mechanism is unknown. This research used bioinformatics approaches to uncover potential molecular mechanisms and drugs for DN and ACS. GSE142153 and GSE19339 were downloaded from the Gene Expression Omnibus (GEO) database. The mutually different expression genes (DEGs) detected in the GSE142153 and GSE19339 datasets were then subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. After a protein-protein interaction network (PPI) analysis, hub genes and transcriptional regulators were tracked by Cytoscape Soft. Finally, potential therapeutic drugs were predicted by the DGIDB drug database. This study identified 274 mutual DEGs from the DN and ACS datasets. Functional analyses indicated that \\\"RNA polymerase II\\\" and the \\\"IL-17 signaling pathway\\\" might play an important role in DN and ACS. Through PPI network construction, the top ten genes were identified. Hub gene and transcription factor interactions were constructed. Seven drugs targeted at VEGFA, IL6, IL1B, and IL1A were evaluated. Four genes and seven drugs were evaluated that could provide a novel perspective for DN and ACS in the future.</p>\",\"PeriodicalId\":23187,\"journal\":{\"name\":\"Tohoku Journal of Experimental Medicine\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tohoku Journal of Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1620/tjem.2024.J048\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tohoku Journal of Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1620/tjem.2024.J048","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Four Genes with Seven Targeted Drugs might be Treatment for Diabetic Nephropathy and Acute Coronary Syndrome.
Diabetes nephropathy (DN) is a main risk factor for acute coronary syndrome (ACS), but the molecular mechanism is unknown. This research used bioinformatics approaches to uncover potential molecular mechanisms and drugs for DN and ACS. GSE142153 and GSE19339 were downloaded from the Gene Expression Omnibus (GEO) database. The mutually different expression genes (DEGs) detected in the GSE142153 and GSE19339 datasets were then subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. After a protein-protein interaction network (PPI) analysis, hub genes and transcriptional regulators were tracked by Cytoscape Soft. Finally, potential therapeutic drugs were predicted by the DGIDB drug database. This study identified 274 mutual DEGs from the DN and ACS datasets. Functional analyses indicated that "RNA polymerase II" and the "IL-17 signaling pathway" might play an important role in DN and ACS. Through PPI network construction, the top ten genes were identified. Hub gene and transcription factor interactions were constructed. Seven drugs targeted at VEGFA, IL6, IL1B, and IL1A were evaluated. Four genes and seven drugs were evaluated that could provide a novel perspective for DN and ACS in the future.
期刊介绍:
Our mission is to publish peer-reviewed papers in all branches of medical sciences including basic medicine, social medicine, clinical medicine, nursing sciences and disaster-prevention science, and to present new information of exceptional novelty, importance and interest to a broad readership of the TJEM.
The TJEM is open to original articles in all branches of medical sciences from authors throughout the world. The TJEM also covers the fields of disaster-prevention science, including earthquake archeology. Case reports, which advance significantly our knowledge on medical sciences or practice, are also accepted. Review articles, Letters to the Editor, Commentary, and News and Views will also be considered. In particular, the TJEM welcomes full papers requiring prompt publication.